Viviane M Gonçalves

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2864690/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification. Applied Microbiology and Biotechnology, 2022, 106, 1011-1029.	1.7	6
2	Pneumococcal Surface Protein A-Hybrid Nanoparticles Protect Mice from Lethal Challenge after Mucosal Immunization Targeting the Lungs. Pharmaceutics, 2022, 14, 1238.	2.0	6
3	Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium. Applied Microbiology and Biotechnology, 2021, 105, 169-183.	1.7	2
4	High stabilization and hyperactivation of a Recombinant β-Xylosidase through Immobilization Strategies. Enzyme and Microbial Technology, 2021, 145, 109725.	1.6	9
5	Evaluation of polymer choice on immunogenicity of chitosan coated PLGA NPs with surface-adsorbed pneumococcal protein antigen PspA4Pro. International Journal of Pharmaceutics, 2021, 599, 120407.	2.6	10
6	Strategies for the Production of Soluble Interferon-Alpha Consensus and Potential Application in Arboviruses and SARS-CoV-2. Life, 2021, 11, 460.	1.1	3
7	Optimization of Expression and Purification of Schistosoma mansoni Antigens in Fusion with Rhizavidin. Molecular Biotechnology, 2021, 63, 983-991.	1.3	2
8	Robust Immune Response Induced by Schistosoma mansoni TSP-2 Antigen Coupled to Bacterial Outer Membrane Vesicles. International Journal of Nanomedicine, 2021, Volume 16, 7153-7168.	3.3	4
9	Modeling and simulation of anion exchange chromatography for purification of proteins in complex mixtures. Journal of Chromatography A, 2020, 1613, 460685.	1.8	17
10	Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced in Escherichia coli. Vaccines, 2020, 8, 492.	2.1	18
11	Cost analysis based on bioreactor cultivation conditions: Production of a soluble recombinant protein using Escherichia coli BL21(DE3). Biotechnology Reports (Amsterdam, Netherlands), 2020, 26, e00441.	2.1	37
12	Process intensification for production of Streptococcus pneumoniae whole ell vaccine. Biotechnology and Bioengineering, 2020, 117, 1661-1672.	1.7	2
13	Optimization and scale-up production of Zika virus ΔNS1 in Escherichia coli: application of Response Surface Methodology. AMB Express, 2020, 10, 1.	1.4	87
14	Progress in mucosal immunization for protection against pneumococcal pneumonia. Expert Review of Vaccines, 2019, 18, 781-792.	2.0	8
15	Children as curators: how to incorporate young visitors' voices into the elaboration and evaluation of a microbiology exhibition. Historia, Ciencias, Saude - Manguinhos, 2019, 26, 85-101.	0.1	1
16	A new vector for heterologous gene expression in Escherichia coli with increased stability in the absence of antibiotic. Plasmid, 2018, 98, 22-30.	0.4	5
17	Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection. PLoS ONE, 2018, 13, e0191692.	1.1	40
18	IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine. Vaccine, 2017, 35, 1306-1315.	1.7	24

#	Article	IF	CITATIONS
19	Production and purification of an untagged recombinant pneumococcal surface protein A (PspA4Pro) with high-purity and low endotoxin content. Applied Microbiology and Biotechnology, 2017, 101, 2305-2317.	1.7	17
20	Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies. Vaccine Journal, 2017, 24, .	3.2	12
21	DEVELOPMENT OF A NEW PROCESS FOR PURIFICATION OF CAPSULAR POLYSACCHARIDE FROM Streptococcus pneumoniae SEROTYPE 14. Brazilian Journal of Chemical Engineering, 2016, 33, 435-443.	0.7	7
22	Recombinant protein production by engineered Escherichia coli in a pressurized airlift bioreactor: A techno-economic analysis. Chemical Engineering and Processing: Process Intensification, 2016, 103, 63-69.	1.8	12
23	ON-LINE MONITORING OF BIOMASS CONCENTRATION BASED ON A CAPACITANCE SENSOR: ASSESSING THE METHODOLOGY FOR DIFFERENT BACTERIA AND YEAST HIGH CELL DENSITY FED-BATCH CULTURES. Brazilian Journal of Chemical Engineering, 2015, 32, 821-829.	0.7	25
24	Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles. International Journal of Pharmaceutics, 2015, 495, 903-912.	2.6	58
25	Capsular polysaccharide production by Streptococcus pneumoniae serotype 1: from strain selection to fed-batch cultivation. Applied Microbiology and Biotechnology, 2015, 99, 10447-10456.	1.7	5
26	A supervision and control tool based on artificial intelligence for high cell density cultivations. Brazilian Journal of Chemical Engineering, 2014, 31, 457-468.	0.7	19
27	Improved capsular polysaccharide production by Streptococcus pneumoniae serotype 14 using continuous cultivation. Biochemical Engineering Journal, 2014, 91, 16-22.	1.8	4
28	Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP production, and stability. Vaccine, 2014, 32, 1113-1120.	1.7	30
29	High cell density co-culture for production of recombinant hydrolases. Biochemical Engineering Journal, 2013, 71, 38-46.	1.8	4
30	On-line prediction of the feeding phase in high-cell density cultivation of rE. coli using constructive neural networks. Computer Methods and Programs in Biomedicine, 2013, 111, 228-248.	2.6	2
31	Conjugation of Polysaccharide 6B from Streptococcus pneumoniae with Pneumococcal Surface Protein A: PspA Conformation and Its Effect on the Immune Response. Vaccine Journal, 2013, 20, 858-866.	3.2	26
32	Intensification of high cell-density cultivations of rE. coli for production of S. pneumoniae antigenic surface protein, PspA3, using model-based adaptive control. Bioprocess and Biosystems Engineering, 2012, 35, 1269-1280.	1.7	24
33	Development of production and purification processes of recombinant fragment of pneumococcal surface protein A in Escherichia coli using different carbon sources and chromatography sequences. Applied Microbiology and Biotechnology, 2012, 94, 683-694.	1.7	32
34	Quantification of capsular polysaccharide of Streptococcus pneumoniae serotype 14 in culture broth samples. Analytical Biochemistry, 2012, 421, 250-255.	1.1	4
35	Humoral immune response of a pneumococcal conjugate vaccine: Capsular polysaccharide serotype 14—Lysine modified PspA. Vaccine, 2011, 29, 8689-8695.	1.7	15
36	Production and purification of recombinant fragment of pneumococcal surface protein A (PspA) in Escherichia coli. Procedia in Vaccinology, 2011, 4, 27-35.	0.4	11

#	Article	IF	CITATIONS
37	Robust artificial intelligence tool for automatic start-up of the supplementary medium feeding in recombinant E. coli cultivations. Bioprocess and Biosystems Engineering, 2011, 34, 891-901.	1.7	9
38	GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine, 2010, 28, 7468-7475.	1.7	85
39	Pneumococcal whole-cell vaccine: optimization of cell growth of unencapsulated Streptococcus pneumoniae in bioreactor using animal-free medium. Journal of Industrial Microbiology and Biotechnology, 2008, 35, 1441-1445.	1.4	15
40	Protection induced by pneumococcal surface protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide. Vaccine, 2008, 26, 2925-2929.	1.7	21
41	A Heuristic Search for Optimal Parameter Values of Three Biokinetic Growth Models for Describing Batch Cultivations of Streptococcus Pneumoniae in Bioreactors. Lecture Notes in Computer Science, 2008, , 359-368.	1.0	3
42	An Empirical Investigation of the Use of a Neural Network Committee for Identifying the Streptococcus Pneumoniae Growth Phases in Batch Cultivations. Lecture Notes in Computer Science, 2008, , 215-224.	1.0	1
43	Introduction of air in the anaerobic culture of Streptococcus pneumoniae serotype 23F induces the release of capsular polysaccharide from bacterial surface into the cultivation medium. Journal of Applied Microbiology, 2006, 101, 1009-1014.	1.4	5
44	Accumulation of organic acids in cultivations of Neisseria meningitidis C. Journal of Industrial Microbiology and Biotechnology, 2006, 33, 869-877.	1.4	7
45	Purification of capsular polysaccharide from Streptococcus pneumoniae serotype 23F by a procedure suitable for scale-up. Biotechnology and Applied Biochemistry, 2003, 37, 283.	1.4	34
46	Optimization of medium and cultivation conditions for capsular polysaccharide production by Streptococcus pneumoniae serotype 23F. Applied Microbiology and Biotechnology, 2002, 59, 713-717.	1.7	30
47	An associated process for the purification of immuno globulin C, catalase, superoxide dismutase and albumin from haemolysed human placenta blood. Biotechnology and Applied Biochemistry, 2001, 34, 135.	1.4	5
48	Albumin purification from human placenta. Biotechnology and Applied Biochemistry, 2000, 31, 101.	1.4	21
49	Crystallization and preliminary X-ray diffraction studies of human catalase. Acta Crystallographica Section D: Biological Crystallography, 1999, 55, 1614-1615.	2.5	6
50	Learning about Microorganisms in Childhood: Four- to Six-Year-Old Children's Voice in Kindergartens and Museums. Revista Brasileira De Pesquisa Em Educação Em Ciências, 0, , 1-25.	0.0	3